Abstract:Isocitric dehydrogenase (IDH)-wild type diffuse gliomas, which have a poorer prognosis than their IDH-mutant counterparts, are also accompanied with high heterogeneity. Here, we aimed to identify the key biological processes associated with the three groups of IDH-wild type diffuse gliomas in 323 patients. By The Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy (cIMPACT-NOW) update 3 recommendation, the three groups are Group A, diffuse astrocytic glioma, World Health Organization (WHO) grade II/III; Group B, diffuse astrocytic glioma, with one (or more) of the three genetic alterations: TERT promoter mutation, EGFR gene amplification, gain of chromosome 7 combined with loss of chromosome 10, WHO grade IV; and Group C, glioblastoma, WHO grade IV. Consistent with their histologic and genetic molecular features, we successfully identified that biological activities associated with "cell cycle" and "cell mitosis" are significantly elevated in Group B compared with Group A; microenvironment-related hallmarks "angiogenesis" and "hypoxia," and biological processes of "extracellular matrix," "immune response," and "positive regulation of transcriptional activities" were more enriched in Group C than Group B. We also constructed a nine-gene signature from differentially expressed genes among the three groups to further stratify the WHO grade IV gliomas (Groups B and C) whose survival cannot be clearly stratified by current classification systems. This signature was an independent prognosis factor for WHO grade IV gliomas and had better prognostic value than other known factors in both training and validation dataset. In addition, the signature risk score was positively correlated with the amount of infiltrated immune cells, expression of immune checkpoints, and the genes enriched in biological processes of "immune response," "cell cycle," and "extracellular matrix." The bioinformatic analysis results were also validated by immunohistochemistry and patient-derived cell proliferation assay. Overall, our findings revealed the key biological processes underlying the new classifications of IDH-wild type diffuse glioma. Meanwhile, we constructed a signature, which could properly stratify the prognosis, cell proliferation activates, extracellular matrix-mediated biological activities, and immune-microenvironment of IDH-wild type WHO grade IV gliomas.

GENE-13. GENOMIC AND RADIOMIC LANDSCAPE OF IDH WILDTYPE-TERT PROMOTER MUTATION IN LOWER-GRADE GLIOMAS

Single-Cell Transcriptomics Reveals the Heterogeneity of the Immune Landscape of IDH-Wild-Type High-Grade Gliomas

IDH mutation-specific radiomic signature in lower-grade gliomas.

Classification Based on Mutations of TERT Promoter and IDH Characterizes Subtypes in Grade II/III Gliomas.

The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma

Integrated Analysis of the Clinical and Molecular Characteristics of IDH Wild-Type Gliomas in the Chinese Glioma Genome Atlas

Transcriptional Characteristics of IDH-Wild Type Glioma Subgroups Highlight the Biological Processes Underlying Heterogeneity of IDH-Wild Type WHO Grade IV Gliomas

[Prognostic Significance of Combined TERT and IDH Gene Mutation Analysis in Diffusely Infiltrating Gliomas].

Molecular and clinical characterization of IDH associated immune signature in lower-grade gliomas

Molecular landscape of IDH‐wild type, pTERT‐wild type adult glioblastomas

High-grade Gliomas with Isocitrate Dehydrogenase Wild-Type and 1p/19q Codeleted: Atypical Molecular Phenotype and Current Challenges in Molecular Diagnosis.

Adult IDH Wild-Type Lower-Grade Gliomas Should Be Further Stratified

Radiomic Study on Preoperative Multi‐modal Magnetic Resonance Images Identifies IDH‐mutant TERT Promoter‐mutant Gliomas

IDH-mutation Status is Associated with Distinct Vascular Gene Expression Signatures in Lower Grade Gliomas.

Molecular landscape of pediatric type IDH wildtype, H3 wildtype hemispheric glioblastomas

Immune Heterogeneity of IDH Glioma Subtypes

A machine learning analysis of a “normal-like” IDH-WT diffuse glioma transcriptomic subgroup associated with prolonged survival reveals novel immune and neurotransmitter-related actionable targets

A Genome-Wide Profiling of Glioma Patients with an IDH1 Mutation Using the Catalogue of Somatic Mutations in Cancer Database

Integrated analysis of the genomic and transcriptional profile of gliomas with isocitrate dehydrogenase-1 and tumor protein 53 mutations

Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses

IDH Clonal Heterogeneity Segregates a Subgroup of Non‐1p/19q Codeleted Gliomas with Unfavourable Clinical Outcome